Nutracon 2013's Best New Ingredient, Appethyl® for acute and long-term appetite suppression is now available to U.S. consumers for the first time. Sales are brisk as Appethyl® is featured on the cover of First for Women, a leading women's magazine.
MOUNT PLEASANT, Utah, Dec. 30, 2014 (GLOBE NEWSWIRE) -- Green PolkaDot Box Incorporated (OTC:GPDB) "GPDB" announced today that it has commenced marketing and sales efforts of the new ingredient known as Appethyl® in the U.S. market. Here is a brief video that accurately describes how Appethyl® works:
"We know that Appethyl® works," says GPDB CEO Rod Smith. "When you have a product that can truly curb appetite and cravings for sweets for a potential marketplace of more than 150 million U.S. customers, you have a formula for success! We anticipate that Appethyl® will become a major revenue generator, a 'gateway' product, a potential flagship product, that can attract consumers who are seeking a healthier dietary lifestyle to Green PolkaDot Box."
Appethyl® is a unique formula that is based on an extract from spinach components—thylakoids—with scientifically identified mechanisms for suppressing hunger signals and promoting reward in the brain. The patented spinach extract, used for acute appetite suppression, is designed to reduce hunger while also reducing blood glucose levels.
Awarded "Best New Ingredient" at the 2013 Nutracon conference, Appethyl® was recognized for scientific merit, efficacy, market potential, safety, innovation and the ability to increase market credibility.
Appethyl® is available to consumers in 7-day trial and 30-day supply packaging. Green PolkaDot Box has plans, commencing this week, to promote Appethyl® through direct response advertising and selling strategies.
Appethyl® is being featured this week on the cover of First for Women magazine, a national publication with over 3 million subscribers. All purchase inquiries are being routed to Green PolkaDot Box via the website Appethyl.com.
In a cost-per-acquisition selling agreement with GPDB, the national advertising agency, Digital Target Marketing, has launched an electronic direct sales campaign to capitalize on the growing national awareness of Appethyl®. Respondents are invited to participate in a free 7-day trial, with the agreement to receive monthly shipments, thereafter.
The Company also announces today that it has entered into an agreement with The Larry Miller Group to begin advertising Appethyl® in all of the Group's 17 MegaPlex Theater locations in Utah, reaching a captive audience of approximately 800,000 consumers, monthly. A 30-second spot invites direct respondents to participate in a free 7-day trial with monthly auto-ship. The success of this program will determine whether similar advertising programs can be conducted in movie theaters, nationally.
The beneficial health effects of Appethyl® have been demonstrated in several clinical studies carried out at Lund University: Appethyl® was found to promote body weight reduction, reduce waist circumference and improve metabolic parameters such as cholesterol and glucose levels. Appethyl® works in a unique triple effect: lowering appetite, delaying absorption of fats, thereby triggering release of satiety hormones, and prolonging uptake of carbohydrates. The effects, use and production of thylakoids are protected via three pending patents, as well as one U.S. patent.
The Company also has solid PR plan in place, working with Lindsey Carnett, President and CEO of Marketing Maven Public Relations, Inc. to promote Appethyl® and its brand on many of the nation's top television stations and print and online media publications and outlets.
Safe Harbor Statement
This release includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as GPDB or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates," "Plans" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.